Skip to content
Saturday 29 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,824.26
+0.29%
DAX
26,569.99
+0.77%
CAC 40
8,401.18
+0.98%
STOXX 50
6,485.67
+0.95%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Thursday 05 May 2016 9:43 am

Fearless future: Virtual reality could help cure paranoia

By: Lynsey Barber

Add as a preferred source on Google

Using a virtual reality (VR) headset could help cure people's paranoia, Oxford researchers have found.

The technology was used in psychological treatment of patients suffering severe paranoia, which affects as much as two per cent of the population in Britain and can leave sufferers unable to leave the house.

The research is a significant step forward in the use of VR technology outside of gaming and entertainment and was hailed as potentially transformative in people's lives.

Read more: I would trust Google with my personal data more than the NHS

Some 30 patients participated in the study, which placed them in the virtual situations – a lift and a train – with characters around them increasing in numbers. The patients had the opportunity to relearn that they were able to feel safe in such situations and manage their anxious feelings.

Half of the participants were told to embrace their normal response to such situations, including defence behaviours, while the other half were encouraged to learn through the situation by approaching the characters.

The researchers found a substantial reduction in the paranoia of the second group and that in real life they felt much less distressed.

“Paranoia all too often leads to isolation, unhappiness, and profound distress. But the exceptionally positive immediate results for the patients in this study show a new route forward in treatment. In just a thirty minute session, those who used the right psychological techniques showed major reductions in paranoia," said University of Oxford psychiatry department professor Daniel Freeman.

“It’s not easy work for patients, since lowering defences takes courage. But as they relearned that being around other people was safe we saw their paranoia begin to melt away. They were then able to go into real social situations and cope far better. This has the potential to be transformative.”

The research is detailed in the latest issue of the British Journal of Psychiatry. More testing is needed, but the Medical Research Council, which backed the study, hailed the potential use of VR for treating major psychiatric problems.

Read more: Virtual reality has arrived – Vive must be seen to be believed

“Virtual reality is proving extremely effective in the assessment and treatment of mental health problems," said Head of neuroscience and mental health at the group, Dr Kathryn Adcock.

"There is a lot of work to do be done in testing the approach for treating delusions but this study shows a new way forward.”

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Tech

Trending Articles

  • Pensioners to hand over bank statements in government benefits crackdown

  • Jamie Carragher: HMRC petitions for Sky Sports star to be declared bankrupt

  • Brewdog founder James Watt hits out at ‘total silence’ over new venture

  • Lloyds Bank and Halifax users unable to use app in latest outage

  • Economists urge Bank of England to halt bond sales as borrowing costs climb

More from Morning Wire

  • Align Technology Prevails in China Patent Infringement Action Against Angelalign

    Business Wire
  • Radiology Partners to Acquire Everlight Radiology, Creating a Global Leader in Teleradiology

    Business Wire
  • New Drill-Free Treatment Helps Patients to Feel at Ease in the Dentist Chair

    Business Wire
  • Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile

    Business Wire
  • Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization

    Business Wire
  • Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™

    Business Wire
  • Limbic Becomes First AI-Led Mental Healthcare Company Selected for FDA TEMPO

    Business Wire
  • Cycle Pharmaceuticals Selects Forma Life Sciences to Establish U.S. Commercial Supply for FDA-Approved CAVHANZA™ (nilotinib) Orally Disintegrating Tablets

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook